体内
腹膜炎
抗生素
肺炎链球菌
化脓性链球菌
动物模型
猫传染性腹膜炎
生物
毒力
微生物学
链球菌
细菌
医学
病理
生物技术
传染病(医学专业)
疾病
金黄色葡萄球菌
生物化学
遗传学
2019年冠状病毒病(COVID-19)
内分泌学
基因
标识
DOI:10.1093/jac/31.suppl_d.55
摘要
The mouse peritonitis model was the first experimental animal model to be used in antibiotic research in 1935, where it proved the effect of Prontosil and derivative sulphonamides against Streptococcus pyogenes in vivo. Since then the mouse peritonitis model has been a natural step in testing antibiotics in vivo before moving to larger animals or humans. Only a few bacteria are naturally virulent to mice, e.g. Streptococcus pneumoniae, but the mice can be rendered susceptible to most human pathogens by inhibition of one or more parts of the natural defence of the animals. For measuring the effect of antibiotics two parameters are usually considered: bacterial counts in fluids or tissues, or death/survival of the animal. Both parameters have flaws, but death is usually used, owing to the ease of observation and quantification by calculation of the 50% effective (protective or curative) doses. With these parameters a number of significant factors of importance for antibiotic effect have been detected or proven in this model. Together with the recent insight into the correlation of pharmacokinetic behaviour between these small animals and man, it is predicted that the mouse peritonitis model will continue to be an important means of studying the effect of antibiotics in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI